拉米夫定治疗活动性肝硬化疗效观察  

Effectiveness of lamivudine therapy for active cirrhosis

作　　者：李文凡[1] 周彬[1] 王玉 李莹[3] 姜瑞[1] 

机构地区：[1]甘肃省人民医院消化科,兰州市730000 [2]临夏人民医院内科 [3]兰州大学一院传染科

出　　处：《实用肝脏病杂志》2005年第6期331-333,共3页Journal of Practical Hepatology

摘　　要：目的观察拉米夫定治疗活动性肝硬化患者的疗效。方法随机选择活动性肝硬化患者57例,其中29例作为观察组,对照组28例使用常规综合治疗。观察组在此基础上加用拉米夫定100mg/日,口服,治疗8个月。观察临床症状和肝功能、Child-Pugh积分、肝纤维化指标以及HBV DNA、e系统血清转换等。结果治疗8个月时,临床症状改善、HBV DNA阴转、肝功能改善,以及有无合并症的出现,观察组均明显优于对照组。结论拉米夫定治疗活动性肝硬化,能抑制病毒复制,改善肝功能,稳定病情,改善预后。Objective To observe the effectiveness of lamivudine on HBV related active cirrhosis. Methods Serum HBV DNA,ALT,ALB,TBil,PTA and Child-Pugh score were observed in 57 patients with active cirrhosis, out of which 28 cases as control group were given routine therapy for 8 months and the 29 cases were given lamivudine 100mg orally daily for 8 months at the base of conventional treatment. Results The clinical symptom and the life quality improved, and the Child-Pugh score declined. The negative rate of serum HBV DNA and liver function in lamivudine group were obvious better than in control group at the end of 8 month treatment. Conclusion lamividine can inhibit HBVDNA in patients with active cirrhosis, therefore improve liver function, stabilize patient＇ s condition and improve prognosis.

关 键 词：肝硬化 乙型肝炎病毒 拉米夫定 

分 类 号：R575.2[医药卫生—消化系统]